Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Genetics
|
| gptkbp:affects |
gptkb:TP53_protein
|
| gptkbp:altered_function |
transcriptional activation
|
| gptkbp:associated_with |
gptkb:Oncology
inflammation cellular proliferation metastasis poor prognosis therapeutic resistance cellular apoptosis radiation sensitivity tumor invasion biomarker development chemotherapy outcomes tumor microenvironment alterations |
| gptkbp:can_detect |
sequencing techniques
|
| gptkbp:cause |
loss of function
|
| gptkbp:clinical_trial |
pathogenic
|
| gptkbp:contributes_to |
genomic instability
|
| gptkbp:disrupts |
DNA binding
|
| gptkbp:genetic_studies |
somatic mutation
|
| https://www.w3.org/2000/01/rdf-schema#label |
TP53 R175 H
|
| gptkbp:influences |
cell cycle regulation
metabolic pathways DNA repair mechanisms tumor heterogeneity cellular signaling pathways cellular adhesion cellular migration personalized medicine strategies chemo-resistance radiotherapy outcomes |
| gptkbp:involved_in |
apoptosis regulation
tumor suppressor pathway |
| gptkbp:is_a |
TP53 variant
|
| gptkbp:is_found_in |
sarcomas
leukemias human tumors |
| gptkbp:is_linked_to |
cellular stress response
epigenetic changes cellular differentiation angiogenesis tumor progression cancer stem cells oncogenic signaling immune evasion genetic counseling. tumor immune evasion prognostic markers |
| gptkbp:is_recognized_by |
gptkb:Oncology
|
| gptkbp:is_studied_in |
clinical trials
oncology research |
| gptkbp:location |
codon 175
|
| gptkbp:prevalence |
varies by cancer type
|
| gptkbp:research_focus |
targeted therapy
|
| gptkbp:resulting_change |
arginine to histidine
|
| gptkbp:type |
missense mutation
|
| gptkbp:bfsParent |
gptkb:TP53
|
| gptkbp:bfsLayer |
5
|